Get the Stockscreener App
0.6838
4.75%
-0.0341
Pre-market:
.68
-0.0038
-0.56%
Mersana Therapeutics Inc stock is traded at $0.6838, with a volume of 5.53M.
It is down -4.75% in the last 24 hours and down -49.72% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
See More
Previous Close:
$0.7179
Open:
$0.757
24h Volume:
5.53M
Relative Volume:
1.31
Market Cap:
$84.47M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-0.4559
EPS:
-1.5
Net Cash Flow:
$-171.05M
1W Performance:
+7.40%
1M Performance:
-49.72%
6M Performance:
-54.72%
1Y Performance:
-81.34%
1-Day Range:
$0.6783
$0.8178
1-Week Range:
$0.5561
$0.8178
52-Week Range:
$0.4913
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.6838 | 84.47M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation - MSN
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics Inc [MRSN] Shares Rise 18.66 % on Wednesday - Knox Daily
Mersana Therapeutics Updates Investor Presentation Online - TipRanks
Investors in cash trouble should check out Mersana Therapeutics Inc (MRSN) - SETE News
MRSNMersana Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference - StockTitan
Apple Swings to Outperformer: Is It a Buy Ahead of Earnings? - The Globe and Mail
MRSN News Today | Why did Mersana Therapeutics stock go down today? - MarketBeat
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $5.57 - MarketBeat
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Average Price Target from Analysts - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Mersana Therapeutics chief development officer sells shares worth $3,444 - MSN
Mersana Therapeutics CEO sells $2,618 in stock - MSN
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Australia
Mersana Therapeutics CEO sells $2,618 in stock By Investing.com - Investing.com Australia
Mersana Therapeutics' SVP sells shares worth $4,912 By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock - MSN
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana therapeutics' chief officer sells shares worth $1,130 - MSN
JPMorgan Chase & Co. Grows Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 - MSN
Mersana Therapeutics’ chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Nigeria
Mersana Therapeutics chief development officer sells shares worth $3,444 By Investing.com - Investing.com South Africa
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 By Investing.com - Investing.com Canada
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):